Literature DB >> 18437399

[Primary and secondary Raynaud's phenomenon].

J H W Distler1.   

Abstract

The term Raynaud's phenomenon describes an abnormal vasospastic response to cold or emotional stress. It is a common condition with a prevalence of 3-5% of the population. Clinically, Raynaud's phenomenon manifests as sharply demarcated colour changes of the skin of the digits that is often accompanied by paraesthesia. Raynaud's phenomenon can be subdivided into primary, or idiopathic, and secondary forms, in the latter of which associated diseases or causes can be identified. The pathogenesis of the disease is incompletely understood. Pathologic changes have been observed primarily in vascular smooth muscle cells, endothelial cells and perineuronal microvasculature. Current therapeutic strategies include supportive treatments, topical therapeutic approaches and systemic medication. Drug therapies with proven efficacy include calcium channel blockers, prostacyclin analogues, fluoxetine, losartan and sildenafil.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18437399     DOI: 10.1007/s00393-008-0282-9

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  66 in total

Review 1.  The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis.

Authors:  A L Herrick; M Matucci Cerinic
Journal:  Clin Exp Rheumatol       Date:  2001 Jan-Feb       Impact factor: 4.473

2.  The influence of different beta-blocking drugs on the peripheral circulation in Raynaud's phenomenon and in hypertension.

Authors:  C Franssen; H Wollersheim; A de Haan; T Thien
Journal:  J Clin Pharmacol       Date:  1992-07       Impact factor: 3.126

3.  Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.

Authors:  M Dziadzio; C P Denton; R Smith; K Howell; A Blann; E Bowers; C M Black
Journal:  Arthritis Rheum       Date:  1999-12

4.  Inefficacy of diltiazem in the treatment of Raynaud's phenomenon with associated connective tissue disease: a double blind placebo controlled study.

Authors:  J da Costa; J A Gomes; J Espirito Santo; M Queirós
Journal:  J Rheumatol       Date:  1987-08       Impact factor: 4.666

5.  Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases.

Authors:  G Spencer-Green
Journal:  Arch Intern Med       Date:  1998-03-23

6.  Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud's phenomenon: implications for vascular dysfunction and progression of disease.

Authors:  Sanjay Rajagopalan; Dana Pfenninger; Christine Kehrer; Anjan Chakrabarti; Emily Somers; Robert Pavlic; Debabrata Mukherjee; Robert Brook; Louis G D'Alecy; Mariana J Kaplan
Journal:  Arthritis Rheum       Date:  2003-07

7.  Characterization of endothelin-binding sites in human skin and their regulation in primary Raynaud's phenomenon and systemic sclerosis.

Authors:  G A Knock; G Terenghi; C B Bunker; H A Bull; P M Dowd; J M Polak
Journal:  J Invest Dermatol       Date:  1993-07       Impact factor: 8.551

8.  An epidemiological survey of Raynaud's phenomenon.

Authors:  J C de Trafford; K Lafferty; C E Potter; V C Roberts; L T Cotton
Journal:  Eur J Vasc Surg       Date:  1988-06

9.  Enalapril in Raynaud's phenomenon.

Authors:  S D Janini; D G Scott; J S Coppock; P A Bacon; M J Kendall
Journal:  J Clin Pharm Ther       Date:  1988-04       Impact factor: 2.512

10.  Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon.

Authors:  M R Zamora; R F O'Brien; R B Rutherford; J V Weil
Journal:  Lancet       Date:  1990-11-10       Impact factor: 79.321

View more
  1 in total

Review 1.  [Capillary microscopy].

Authors:  W Hermann
Journal:  Z Rheumatol       Date:  2016-08       Impact factor: 1.372

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.